An early warning system for emerging drugs of concern in the emergency department: Protocol for the Western Australian Illicit Substance Evaluation (WISE) study
| Autor: | Jessamine Soderstrom, David McCutcheon, Bianca Douglas, Francois Oosthuizen, Ellen MacDonald, Daniel M Fatovich, Mohan Raghavan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Drug medicine.medical_specialty Substance-Related Disorders medicine.drug_class medicine.medical_treatment media_common.quotation_subject 03 medical and health sciences 0302 clinical medicine Humans Medicine Prospective Studies 030212 general & internal medicine Intensive care medicine media_common Protocol (science) Psychotropic Drugs Illicit Substance business.industry 030208 emergency & critical care medicine Western Australia Emergency department Waiver Designer drug Stimulant Early Warning Score Emergency Medicine Early warning system Female Emergency Service Hospital business |
| Zdroj: | Emergency Medicine Australasia. 31:411-416 |
| ISSN: | 1742-6723 1742-6731 |
| DOI: | 10.1111/1742-6723.13185 |
| Popis: | Objective An ever-increasing number of novel psychoactive substances are being detected worldwide. These emerging drugs have been demonstrated to cause toxicity in clusters, and deaths have been reported. We urgently need to learn more about their effects. We report the protocol for the Western Australian Illicit Substance Evaluation (WISE) study, a research project investigating illicit drug use in the ED. Methods Patients can be enrolled if the treating clinician strongly suspects they are currently intoxicated with a stimulant, hallucinogenic or cannabinoid drug; and an i.v. cannula or blood tests are required for routine clinical care. Patients are enrolled under a waiver of consent. A single additional blood tube is collected, de-identified and frozen on site. A temporary link between patient identification number and study identification number is retained for up to 10 business days post-hospital discharge to allow for clinical data collection, before this is destroyed and the patients become permanently de-identified. Samples are transported for external liquid chromatography-mass spectrometry analysis in batches once de-identified. Results The key outcome will be identification of any psychoactive drugs present in the blood sample, together with their respective concentration. This will be linked to the clinical effects, as well as being compared with the substance the patient believed they had taken. Conclusion We consider the novel approach outlined forms a template for an early warning system for emerging drugs of concern, while also providing vital and comprehensive information on current drugs of abuse, their clinical effects and their impact on the health system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text